NASDAQ : HOWL
Werewolf Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.9861 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 47.92M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 47.92M |
| Enterprise Value | 25.94M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 48.60M |
| Shares Outstanding | 48.60M |
| Shares Change (YoY) | +7.56% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 6.62% |
| Owned by Institutions (%) | 42.56% |
| Float | 45.38M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.28 |
| Forward PS | n/a |
| PB Ratio | 2.94 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.91 |
| Quick Ratio | 2.80 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.62 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -119.86% |
| Return on Assets (ROA) | -27.39% |
| Return on Invested Capital (ROIC) | -33.68% |
| Return on Capital Employed (ROCE) | -156.97% |
| Weighted Average Cost of Capital (WACC) | 7.25% |
| Revenue Per Employee | $1.50M |
| Profits Per Employee | -$2.47M |
| Employee Count | 14 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -36.79% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 0.68 |
| Relative Strength Index (RSI) | 50.68 |
| Average Volume (20 Days) | 412,608 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.36M |
| Short Previous Month | 2.51M |
| Short % of Shares Out | 4.85% |
| Short % of Float | 5.19% |
| Short Ratio (days to cover) | 3.83 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 21.00M |
| Gross Profit | -5.19M |
| Operating Income | -25.57M |
| Pretax Income | -34.61M |
| Net Income | -34.61M |
| EBITDA | -21.92M |
| EBIT | -25.57M |
| Loss Per Share | -$0.75 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 21.99M |
| Total Debt | n/a |
| Net Cash | 21.99M |
| Net Cash Per Share | $0.45 |
| Equity (Book Value) | 16.29M |
| Book Value Per Share | 0.34 |
| Working Capital | 15.03M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -30.15M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.65M |
| Net Borrowing | -32.41M |
| Free Cash Flow | -30.15M |
| FCF Per Share | -$0.62 |
Margins
| Measure | Value |
|---|
| Gross Margin | -24.69% |
| Operating Margin | -121.78% |
| Pretax Margin | -164.82% |
| Profit Margin | -164.82% |
| EBITDA Margin | -104.39% |
| EBIT Margin | -121.78% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.56% |
| Shareholder Yield | n/a |
| Earnings Yield | -76.07% |
| FCF Yield | -62.91% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -26.51 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |